Titre (en)
Analysis
2020
Racine
Analysis
2020
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Analysis (2020)

Index « Titre (en) » - entrée « secondary »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
seattle < secondary < secretion  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
000065 (2020) Ian Pirker [Suisse] ; Andrea Rubbert-Roth [Suisse] ; Johannes Von Kempis [Suisse] ; Martin Fehr [Suisse] ; Thomas Neumann [Suisse]Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy.
000134 (2020) Ayush Gupta [Inde] ; Narendra Kumar Bagri [Inde] ; Saroj Kumar Tripathy [Inde] ; Adarsh Barwad [Inde] ; Ravi Hari Phulware [Inde] ; Pankaj Hari [Inde]Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
000394 (2020) Alberto Meneguzzo ; Annalisa Lazzarotto ; Mauro AlaibacEruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer
000432 (2020) Kosuke Ebina [Japon] ; Toru Hirano [Japon] ; Yuichi Maeda [Japon] ; Wataru Yamamoto [Japon] ; Motomu Hashimoto [Japon] ; Koichi Murata [Japon] ; Tohru Takeuchi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Akira Onishi [Japon] ; Sadao Jinno [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Keiichi Yamamoto [Japon] ; Atsushi Kumanogoh [Japon] ; Makoto Hirao [Japon]Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
000440 (2020) Robert David Sandler [Royaume-Uni] ; Rachel Scarlett Tattersall [Royaume-Uni] ; Helene Schoemans [Belgique] ; Raffaella Greco [Italie] ; Manuela Badoglio [France] ; Myriam Labopin [France] ; Tobias Alexander [Allemagne] ; Kirill Kirgizov [Russie] ; Montserrat Rovira [Espagne] ; Muhammad Saif [Royaume-Uni] ; Riccardo Saccardi [Italie] ; Julio Delgado [Espagne] ; Zinaida Peric [Croatie] ; Christian Koenecke [Allemagne] ; Olaf Penack [Allemagne] ; Grzegorz Basak [Pologne] ; John Andrew Snowden [Royaume-Uni]Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i -k "secondary" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i  \
                -Sk "secondary" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    Title.i
   |clé=    secondary
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021